GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adbiotech Co Ltd (XKRX:179530) » Definitions » Piotroski F-Score

Adbiotech Co (XKRX:179530) Piotroski F-Score : 4 (As of May. 28, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Adbiotech Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Adbiotech Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Adbiotech Co's Piotroski F-Score or its related term are showing as below:

XKRX:179530' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 4
Current: 4

During the past 5 years, the highest Piotroski F-Score of Adbiotech Co was 4. The lowest was 2. And the median was 4.


Adbiotech Co Piotroski F-Score Historical Data

The historical data trend for Adbiotech Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adbiotech Co Piotroski F-Score Chart

Adbiotech Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A N/A 4.00 4.00

Adbiotech Co Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 2.00 4.00 4.00

Competitive Comparison of Adbiotech Co's Piotroski F-Score

For the Biotechnology subindustry, Adbiotech Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adbiotech Co's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adbiotech Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Adbiotech Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -400.89 + -947.15 + -1292.152 + -4245.289 = ₩-6,885 Mil.
Cash Flow from Operations was -3349.514 + -751.127 + 2923.484 + -536.563 = ₩-1,714 Mil.
Revenue was 2370.886 + 2757.403 + 2300.922 + 2930.338 = ₩10,360 Mil.
Gross Profit was 738.235 + 1009.034 + 747.414 + 1392.217 = ₩3,887 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(27638.908 + 32156.925 + 30461.64 + 28093.228 + 22896.225) / 5 = ₩28249.3852 Mil.
Total Assets at the begining of this year (Mar23) was ₩27,639 Mil.
Long-Term Debt & Capital Lease Obligation was ₩3,682 Mil.
Total Current Assets was ₩8,699 Mil.
Total Current Liabilities was ₩12,727 Mil.
Net Income was -1325.109 + -264.793 + 5033.733 + -535.522 = ₩2,908 Mil.

Revenue was 3410.372 + 1860.857 + 2333.563 + 3042.738 = ₩10,648 Mil.
Gross Profit was 1214.823 + 374.872 + 255.36 + 723.253 = ₩2,568 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(29657.626 + 28567.625 + 27034.602 + 31018.134 + 27638.908) / 5 = ₩28783.379 Mil.
Total Assets at the begining of last year (Mar22) was ₩29,658 Mil.
Long-Term Debt & Capital Lease Obligation was ₩2,993 Mil.
Total Current Assets was ₩11,658 Mil.
Total Current Liabilities was ₩12,520 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Adbiotech Co's current Net Income (TTM) was -6,885. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Adbiotech Co's current Cash Flow from Operations (TTM) was -1,714. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-6885.481/27638.908
=-0.24912276

ROA (Last Year)=Net Income/Total Assets (Mar22)
=2908.309/29657.626
=0.09806277

Adbiotech Co's return on assets of this year was -0.24912276. Adbiotech Co's return on assets of last year was 0.09806277. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Adbiotech Co's current Net Income (TTM) was -6,885. Adbiotech Co's current Cash Flow from Operations (TTM) was -1,714. ==> -1,714 > -6,885 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=3681.634/28249.3852
=0.13032616

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=2993.074/28783.379
=0.10398619

Adbiotech Co's gearing of this year was 0.13032616. Adbiotech Co's gearing of last year was 0.10398619. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=8698.803/12727.494
=0.6834655

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=11658.083/12519.515
=0.93119286

Adbiotech Co's current ratio of this year was 0.6834655. Adbiotech Co's current ratio of last year was 0.93119286. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Adbiotech Co's number of shares in issue this year was 9.149. Adbiotech Co's number of shares in issue last year was 9.14. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3886.9/10359.549
=0.37519973

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2568.308/10647.53
=0.24121162

Adbiotech Co's gross margin of this year was 0.37519973. Adbiotech Co's gross margin of last year was 0.24121162. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=10359.549/27638.908
=0.37481759

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=10647.53/29657.626
=0.35901491

Adbiotech Co's asset turnover of this year was 0.37481759. Adbiotech Co's asset turnover of last year was 0.35901491. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Adbiotech Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Adbiotech Co  (XKRX:179530) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Adbiotech Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Adbiotech Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Adbiotech Co (XKRX:179530) Business Description

Traded in Other Exchanges
N/A
Address
39, Geodudanji 1-gil, Dongnae-myeon, Gangwon-do, Chuncheon, KOR, 24398
Adbiotech Co Ltd is a life science company. It develops a vaccine and antibiotic-friendly substances such as IgY, Immunoglobulin in Yolk for human, animal and fish oral antibody products, and functional cosmetics and food additives. The company aim to develop Helico IgY, Cholesterol IgY, and Ulcerative Colitis natural product medicines.

Adbiotech Co (XKRX:179530) Headlines

No Headlines